Chemistry:Imlunestrant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | LY3484356 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H24F4N2O3 |
| Molar mass | 524.516 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Imlunestrant is an experimental selective estrogen receptor degrader developed by Eli Lilly and Company for the treatment of some types of breast cancer.[1][2][3]
References
- ↑ Neven, P.; Stahl, N.; Losada, M.J. Vidal; Jimenez, M. Martin; Kaufman, P.A.; Harbeck, N.; Hunt, K.; Carter, S.A. et al. (October 2023). "273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2". Annals of Oncology 34: S292–S293. doi:10.1016/j.annonc.2023.09.470.
- ↑ Jhaveri, Komal; O’Shaughnessy, Joyce; Andre, Fabrice; Goetz, Matthew P.; Harbeck, Nadia; Martín, Miguel; Bidard, Francois-Clement; Thomas, Zachary M. et al. (1 March 2023). "Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET". Cancer Research 83 (5_Supplement): OT1–01–02-OT1-01-02. doi:10.1158/1538-7445.SABCS22-OT1-01-02.
- ↑ Jhaveri, Komal L.; Jeselsohn, Rinath; Lim, Elgene; Hamilton, Erika P.; Yonemori, Kan; Beck, J. Thaddeus; Kaufman, Peter A.; Sammons, Sarah et al. (1 June 2022). "A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.". Journal of Clinical Oncology 40 (16_suppl): 1021. doi:10.1200/JCO.2022.40.16_suppl.1021.
 |  |
